To report SUSPECTED ADVERSE REACTIONS, contact argenx at 1-833-argx411 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
Resource Library
To report SUSPECTED ADVERSE REACTIONS, contact argenx at 1-833-argx411 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
To report SUSPECTED ADVERSE REACTIONS, contact argenx at 1-833-argx411 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
ACR Posters and Presentations 2025
Treatment of Sjögren's disease by blocking FcRn: clinical and translational data from RHO, a phase 2 randomized, placebo-controlled, double-blind, proof-of-concept study with efgartigimod
October 24, 2025
Treatment of Sjögren's disease by blocking FcRn: clinical and translational data from RHO, a phase 2 randomized, placebo-controlled, double-blind, proof-of-concept study with efgartigimod
October 24, 2025
Pharmaceutical blockade of the neonatal Fc gamma receptor ameliorates autoimmunity, inflammation and fibrosis in the Topoisomerase I mouse model of systemic sclerosis
October 25, 2025
Pharmaceutical blockade of the neonatal Fc gamma receptor ameliorates autoimmunity, inflammation and fibrosis in the Topoisomerase I mouse model of systemic sclerosis
October 25, 2025
Effect of Efgartigimod PH20 SC on Total Improvement Score, Its Core Set Measures, and Patient/Clinician Impressions of Change: Results From the Phase 2 ALKIVIA Study of Adults With Active Idiopathic Inflammatory Myopathy
October 25, 2025
Effect of Efgartigimod PH20 SC on Total Improvement Score, Its Core Set Measures, and Patient/Clinician Impressions of Change: Results From the Phase 2 ALKIVIA Study of Adults With Active Idiopathic Inflammatory Myopathy
October 25, 2025
ACR Posters and Presentations 2026
Handouts
Efgartigimod Mechanism of Action Handout
August 31, 2026
Efgartigimod Mechanism of Action Handout
August 31, 2026
Myositis Disease State Handout
August 31, 2026
Myositis Disease State Handout
August 31, 2026
Sjögren’s Disease Disease State Handout
August 31, 2026
Sjögren’s Disease Disease State Handout
August 31, 2026
Immunology Innovation Program Flyer
August 31, 2026
Immunology Innovation Program Flyer
August 31, 2026
Cross-indication Externally Sponsored Research Handout
August 31, 2026
Cross-indication Externally Sponsored Research Handout
August 31, 2026
VYVGART/VYVGART HYTRULO: Generalized Myasthenia Gravis (gMG) and Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Cross-indication Safety Handout
August 31, 2026
VYVGART/VYVGART HYTRULO: Generalized Myasthenia Gravis (gMG) and Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Cross-indication Safety Handout
August 31, 2026
Efgartigimod in Sjögren’s Disease: RHO Study Clinical Data Summary
August 31, 2026
Efgartigimod in Sjögren’s Disease: RHO Study Clinical Data Summary
August 31, 2026
To report SUSPECTED ADVERSE REACTIONS, contact argenx at 1-833-argx411 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
VYVGART is a registered trademark of argenx. VYVGART Hytrulo is a trademark of argenx.
© 2026 argenx MED-US-NON-2400036 v6 04/2026. All Rights Reserved.